Trial document




drksid header

  DRKS00013526

Trial Description

start of 1:1-Block title

Title

Evaluation of suitable criteria for the therapy of uterine fibroids by MR-guided high-intensity focused ultrasound (MR-HIFU)

end of 1:1-Block title
start of 1:1-Block acronym

Trial Acronym

HIFU-Myom

end of 1:1-Block acronym
start of 1:1-Block url

URL of the Trial

[---]*

end of 1:1-Block url
start of 1:1-Block public summary

Brief Summary in Lay Language


end of 1:1-Block public summary
start of 1:1-Block scientific synopsis

Brief Summary in Scientific Language

Over the last few decades, minimally invasive, image-guided interventions have gained in importance as an alternative to conventional open surgery or as a supplement to classical radiotherapy or chemotherapy, especially for the local, gentle treatment of tumorous diseases. The special feature of the HIFU compared to the other ablation methods is the completely non-invasive procedure, since the ultrasound source is located extracorporeally.
The Philips Sonalleve System is a CE-certified MR-HIFU system that enables selective tissue heating to 60-80° C under MR image control and MR real-time temperature measurement. Especially for the treatment of uterine fibroids, this approach has already been evaluated as a promising and gentle alternative, which is used in over 150 selected, specialized centers worldwide.
For optimal performance, reliable visualization of the target tissue as well as continuous monitoring of tissue destruction are important. To control the therapy, MRI has proven to be the method of choice due to the combination of excellent soft tissue contrast, multiplanar layering and the absence of ionizing radiation in addition to diagnostic ultrasound. In addition, unlike the US, MRI offers the possibility of true thermometry and diffusion imaging for advanced focal focus imaging.
The MR-HIFU combines the accuracy of MRI imaging with gentle treatment through the use of ultrasound radiation. The method is characterized mainly by the low complication rates and low side effects with overall fast symptomatic improvement. Since 2003, further studies on the use of uterine fibroids have been published. This enabled the MR-HIFU to gain a legitimate status in myoma therapy over time. Compared to current minimally invasive gold standard, the uterine artery embolization (UAE), MR-HIFU achieved a similar result in terms of post-interventional symptom relief.
The aim of the planned MR-HIFU interventions presented here is the evaluation of suitable criteria for the treatment of uterine fibroids by means of MR guided high-intensity focused ultrasound for routine implementation in the Department of Radiology of the Ludwig-Maximilians University Munich. In addition, the pain load as well as the safety and ergonomics should be evaluated within the scope of the application. Furthermore, the cost-effectiveness of the method compared to the UAE and the surgical procedures myomectomy or hysterectomy should be examined.

end of 1:1-Block scientific synopsis
start of 1:1-Block organizational data

Organizational Data

  •   DRKS00013526
  •   2018/05/25
  •   [---]*
  •   yes
  •   Approved
  •   18-043, Ethik-Kommission der Medizinischen Fakultät der Ludwig-Maximilians-Universität München
end of 1:1-Block organizational data
start of 1:n-Block secondary IDs

Secondary IDs

  •   internes Register  (LMU-RAD00010)
end of 1:n-Block secondary IDs
start of 1:N-Block indications

Health Condition or Problem studied

  •   D25.0 -  Submucous leiomyoma of uterus
  •   D25.1 -  Intramural leiomyoma of uterus
end of 1:N-Block indications
start of 1:N-Block interventions

Interventions/Observational Groups

  •   The patient is evaluated interdisciplinarily by the treating gynecologist with the request for treatment of a complaint-causing finding (uterine fibroma) and is called for an indication for radiological-interventional therapy.
    A pre-interventional contrast enhanced ultrasound examination is performed and intravenous access is established. In addition, for the duration of the MR-HIFU (high-intensity focused ultrasound) therapy, the installation of a urinary bladder catheter. Subsequently, the patient is positioned on the MRI with built-in HIFU device. Pre-intervention MR images are taken to assess the target region and adjacent structures. Finally, the positioning of the patient takes place. A mild i.v. sedation and analgesation ensures that the patient receives little from the relatively long treatment (about 2-3 h). At 3, 6 and 12 months after successful MR-HIFU therapy a follow-up visit is planned. During that the UFS-QOL quality of life questionnaire will be handed out and a follow-up and MRI scan will be performed.
end of 1:N-Block interventions
start of 1:1-Block design

Characteristics

  •   Interventional
  •   [---]*
  •   Single arm study
  •   Open (masking not used)
  •   [---]*
  •   Uncontrolled/Single arm
  •   Prognosis
  •   Single (group)
  •   N/A
  •   N/A
end of 1:1-Block design
start of 1:1-Block primary endpoint

Primary Outcome

Achievement of the final follow-up (12 months) or performing any additional myoma therapy (e.g., myomactomy, hysterectomy, or Radiofrequency Ablation (RFA))

end of 1:1-Block primary endpoint
start of 1:1-Block secondary endpoint

Secondary Outcome

/

end of 1:1-Block secondary endpoint
start of 1:n-Block recruitment countries

Countries of Recruitment

  •   Germany
end of 1:n-Block recruitment countries
start of 1:n-Block recruitment locations

Locations of Recruitment

  • University Medical Center 
end of 1:n-Block recruitment locations
start of 1:1-Block recruitment

Recruitment

  •   Actual
  •   2018/06/06
  •   30
  •   Monocenter trial
  •   National
end of 1:1-Block recruitment
start of 1:1-Block inclusion criteria

Inclusion Criteria

  •   Female
  •   18   Years
  •   65   Years
end of 1:1-Block inclusion criteria
start of 1:1-Block inclusion criteria add

Additional Inclusion Criteria

1. Age of at least 18 years.
2. Current creatinine
3. Indication for local ablative therapy by means of HIFU
4. Accessibility of the fibroid / fibroids with HIFU
5. Funaki Type I-II
6. Signed declaration of consent with compliance incl. Follow-up treatment with compliance including follow-up treatment
7. Size of fibroid <12 cm
8. Exclusion of a leiomyosarcoma
9. Signed declaration of consent

end of 1:1-Block inclusion criteria add
start of 1:1-Block exclusion criteria

Exclusion Criteria

1. Taking Ulipristalacetat (Esmya) over the past 6 months
2. General MRI contraindications (pacemakers, metal parts)
3. contrast agent allergy
4. Significantly reduced general condition
5. Massive obesity (BMI> 40)
6. Patients with mental / psychiatric disorders
7. pregnancy
8. intrauterine Device
9. Funaki Type III-IV
10. Pedunculated serous fibroid
11. Detection of a Leiomyosarcoma

end of 1:1-Block exclusion criteria
start of 1:n-Block addresses

Addresses

  • start of 1:1-Block address primary-sponsor
    • Klinikum der Universität München, Campus Großhadern
    • Marchioninistraße 15
    • 81377  München
    • Germany
    end of 1:1-Block address primary-sponsor
    start of 1:1-Block address contact primary-sponsor
    end of 1:1-Block address contact primary-sponsor
  • start of 1:1-Block address scientific-contact
    • Klinik und Poliklinik für Radiologie Klinikum der Universität München
    • Mr.  Dr.  Bastian  Sabel 
    • Marchioninistr. 15
    • 81377  München
    • Germany
    end of 1:1-Block address scientific-contact
    start of 1:1-Block address contact scientific-contact
    end of 1:1-Block address contact scientific-contact
  • start of 1:1-Block address public-contact
    • Klinik und Poliklinik für Radiologie Klinikum der Universität München Campus Großhadern
    • Ms.  Christel  Besseler 
    • Marchioninistr. 15
    • 81377  München
    • Germany
    end of 1:1-Block address public-contact
    start of 1:1-Block address contact public-contact
    end of 1:1-Block address contact public-contact
end of 1:n-Block addresses
start of 1:n-Block material support

Sources of Monetary or Material Support

  • start of 1:1-Block address materialSupport
    • Klinik und Poliklinik für Radiologie Klinikum der Universität München Campus Großhadern
    • Mr.  Prof.  Jens  Ricke 
    • Marchioninistr. 15
    • 81377  München
    • Germany
    end of 1:1-Block address materialSupport
    start of 1:1-Block address contact materialSupport
    •   (089) 4400-4400 72750
    •   [---]*
    •   [---]*
    •   [---]*
    end of 1:1-Block address contact materialSupport
end of 1:n-Block material support
start of 1:1-Block state

Status

  •   Recruiting ongoing
  •   [---]*
end of 1:1-Block state
start of 1:n-Block publications

Trial Publications, Results and other Documents

  • [---]*
end of 1:n-Block publications
* This entry means the parameter is not applicable or has not been set.